Article thumbnail

The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia

By Geller Jack and Sullivan Michael J

Abstract

<p>Abstract</p> <p>Background</p> <p>Finasteride, a 5 alpha reductase inhibitor, is an established treatment for benign prostatic hyperplasia. The recommended dosage is 5 mg a day, however case reports have show effectiveness with lower doses. The objective of the current study was to determine in men with benign prostatic hyperplasia, previously treated for at least one year with finasteride 5 mg daily, if they will maintain subjective and objective improvements in urinary obstruction when treated with 2.5 mg of finasteride daily for one year.</p> <p>Methods</p> <p>In an open label, prospective study, 40 men with benign prostatic hyperplasia, previously treated for at least one year with 5 mg of finasteride, took 2.5 mg of finasteride daily for one year. Measurements included AUA symptom score, maximum flow rate, voided volume and PSA.</p> <p>Results</p> <p>There were no significant changes in maximum flow rate, voided volume, or AUA symptom score after one year of finasteride 2.5 mg daily therapy. PSA increased significantly, p < .01, after one year of finasteride 2.5 mg daily, 2.0 +1.4 ng/ml, when compared to finasteride 5 mg daily, 1.4+ 1.0 ng/ml.</p> <p>Conclusions</p> <p>The daily dose of finasteride can be reduced to 2.5 mg daily without significant effect on subjective and objective measures of urinary obstruction. Although statistically significant increases in PSA are noted when reducing the daily finasteride dose from 5 mg to 2.5 mg, the clinical significance of a mean .6 ng/ml increase in PSA is questionable.</p

Topics: Diseases of the genitourinary system. Urology, RC870-923
Publisher: BMC
Year: 2002
DOI identifier: 10.1186/1471-2490-2-2
OAI identifier: oai:doaj.org/article:463e6499e0f6414cb5a98073a96ddce7
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1471-2490 (external link)
  • http://www.biomedcentral.com/1... (external link)
  • https://doaj.org/article/463e6... (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles